drugset
drugset / Trial / NCT04239989

Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant

NCT04239989 ↗

Phase 1 Terminated 8 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies how well itacitinib works for the treatment of bronchiolitis obliterans syndrome after donor hematopoietic cell transplant. Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2021-10-08
Primary completion
2025-10-31
Completion
2025-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Itacitinib Small molecule — Oral

Indications

bronchiolitis obliterans syndrome